Illumina, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on the stock and has a $150.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kyle Mikson CFA has given his Hold rating due to a combination of factors, balancing Illumina’s current positioning with rising competitive risks. He notes that Illumina’s 2026 revenue targets still appear achievable, even as new high-throughput short-read platforms from Roche, Element, and Ultima are pushing genome sequencing prices meaningfully below Illumina’s current $200-per-genome level.
At the same time, Mikson highlights that Roche’s AXELIOS platform, reusable chips, and eventual IVD-focused system could pressure Illumina over the medium to long term, especially in fast-growing clinical settings where speed and cost are critical. While Illumina’s ongoing product roadmap, including multiomics offerings and planned enhancements to NovaSeq X, may soften the competitive impact, the intensifying landscape justifies a neutral stance rather than a more constructive rating at this stage.
According to TipRanks, Mikson CFA is an analyst with an average return of -1.4% and a 37.50% success rate. Mikson CFA covers the Healthcare sector, focusing on stocks such as Illumina, GeneDx Holdings, and Caris Life Sciences, Inc..